MCID: BLD034
MIFTS: 55

Bile Duct Carcinoma

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Carcinoma

MalaCards integrated aliases for Bile Duct Carcinoma:

Name: Bile Duct Carcinoma 12 14 69
Bile Duct Cancer 50 52 41
Bile Duct Neoplasms 42 69
Malignant Tumor of Extrahepatic Bile Duct 69
Carcinoma of Extrahepatic Bile Duct 69
Extrahepatic Bile Duct Cancer 50

Classifications:



External Ids:

Disease Ontology 12 DOID:4897
MeSH 42 D001650
NCIt 47 C27814
SNOMED-CT 64 70179006
UMLS 69 C0740277

Summaries for Bile Duct Carcinoma

NIH Rare Diseases : 50 the following summary is from orphanet, a european reference portal for information on rare diseases and orphan drugs.orpha number: 70567disease definitioncholangiocarcinoma (cca) is a biliary tract cancer (btc, see this term) originating in the epithelium of the biliary tree, either intra or extra hepatic.epidemiologythe prevalence is unknown but it accounts for approximately 3% of gastrointestinal tumors and 10-15% of all hepatobiliary malignancies.clinical descriptioncca can occur in the intra or extra-hepatic biliary tract. a specific type of extra-hepatic cca known as a klatskin tumor (see this term) occurs at the junction where the left and right hepatic bile ducts meet the common bile duct (cbd). it is slightly more prevalent in males than females (1.3:1.0) and usually presents in the fifth to seventh decade of life. clinical manifestations are not usually noted until an advanced disease stage. extra-hepatic cca manifests with signs of cholestasis (jaundice, pale stools, dark urine, pruritus), malaise, weight loss and/or progressive weakness. intra-hepatic cca may present with an abdominal mass or with non-specific symptoms of decreased appetite, weight loss, abdominal pain and malaise.etiologythe etiology is unknown and most cases of cca occur sporadically. risk factors include primary sclerosing cholangitis (see this term), secondary sclerosing cholangitis, chronic typhoid carriage, parasitic infections (opisthochis viverrini and clonorchis sinensis), exposure to thorotrast (x-ray contrast medium) and choledochal cysts, all of which cause chronic biliary inflammation.diagnostic methodsdiagnosis is suspected on clinical and laboratory findings. serum carbohydrate antigen (ca) 19-9 is the glycoprotein tumor marker most often used in the diagnosis of cca. it is found to be elevated in 85% of patients. increased cea levels are also noted. extra-hepatic tumors cause increased levels of alkaline phosphate (alp), conjugated bilirubin and gamma-glutamyl transpeptidase (ggt) while intra-hepatic have only slightly elevated alp levels. abdominal imaging, visualization of the biliary tree and biopsies of the lesion are necessary for diagnosis. magnetic resonance cholangiopancreatography (mrcp) provides information on intrahepatic metastases, biliary anatomy and tumor extension and is used in the staging of cca. it has been advocated to replace endoscopic retrograde cholangiopancreatography (ercp), a more invasive method. visualization of the biliary tree and samples through brush cytology or bile duct biopsies are obtained with ercp. a needle biopsy is performed in those with a liver mass. extra-hepatic cca is further divided into anatomical subtypes according to the bismuth classification and a disease stage is given. ultrasound, and contrast enhanced helical computerized computed tomography (ct) can be used in visualizing the extent of disease.differential diagnosisintra-hepatic cca is often mistaken for metastatic adenocarcinoma. carcinoma of the gallbladder (see this term), benign strictures and mirizzi syndrome should be excluded.management and treatmentsurgical resection is the only potentially curative treatment for cca but recurrences after surgery are frequent. unfortunately cca is often diagnosed as unresectable because of local extension and/or metastases. distal cca arising from the cbd is often treated by pancreatoduodenectomy. more proximal cca needs hepatic resection. palliative management involves biliary drainage by inserting metal stents in the biliary tree to release the blockage. adjuvant chemotherapy after surgery or palliative chemotherapy for unresectable cca is indicated. gemcitabine combined with cisplatin therapy is the standard treatment for unresectable biliary tract cancers, including cca.prognosisas proximal cca is usually not diagnosed until a late stage of disease, prognosis is poor with 5-year survival rates of 20-50% after resection and almost 0% in unresectable tumors. death is often due to biliary sepsis, cancer cachexia, malnutrition and liver failure.visit the orphanet disease page for more resources. last updated: 9/1/2012

MalaCards based summary : Bile Duct Carcinoma, also known as bile duct cancer, is related to intrahepatic cholangiocarcinoma and klatskin's tumor, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Bile Duct Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Development HGF signaling pathway and Cytoskeletal Signaling. The drugs Oxaliplatin and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and small intestine, and related phenotypes are cardiovascular system and cellular

MedlinePlus : 41 your liver makes a digestive juice called bile. your gallbladder stores it between meals. when you eat, your gallbladder pushes the bile into tubes called bile ducts. they carry the bile to your small intestine. the bile helps break down fat. it also helps the liver get rid of toxins and wastes. bile duct cancer is rare. it can happen in the parts of the bile ducts that are outside or inside the liver. cancer of the bile duct outside of the liver is much more common. risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. symptoms can include jaundice itchy skin fever abdominal pain tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. treatments include surgery, radiation therapy, and chemotherapy. nih: national cancer institute

Disease Ontology : 12 A bile duct cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia : 72 Cholangiocarcinoma, also known as bile duct cancer, is a form of cancer that is composed of mutated... more...

Related Diseases for Bile Duct Carcinoma

Diseases related to Bile Duct Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 215)
id Related Disease Score Top Affiliating Genes
1 intrahepatic cholangiocarcinoma 32.6 CDX2 KRT20 KRT7
2 klatskin's tumor 32.1 KRT7 MUC1 MUC4
3 situs inversus 30.7 MUC1 MUC2
4 liver disease 30.3 KRT19 MUC1 MUC4
5 hepatocellular carcinoma 29.1 ABCC3 CCND1 CDH1 FASLG KRT19 KRT7
6 adenosquamous bile duct carcinoma 12.2
7 bile duct carcinoma in situ 12.1
8 common bile duct neoplasm 12.1
9 biliary tract neoplasm 11.1
10 extrahepatic bile duct small cell adenocarcinoma 11.0
11 extrahepatic bile duct adenocarcinoma 11.0
12 bile duct adenocarcinoma 11.0
13 bile duct clear cell adenocarcinoma 10.9 CDX2 MUC2
14 renal pelvis urothelial papilloma 10.8 CDH1 TP53
15 kidney benign neoplasm 10.8 CDH1 MUC1 MUC2
16 bestiality 10.8 MUC1 MUC2 MUC4
17 tendon sheath lipoma 10.8 PTGS2 TP53
18 idiopathic central precocious puberty 10.8 MUC2 MUC4
19 cribriform carcinoma 10.8 CDH1 KRT20 MUC1
20 rhinosporidiosis 10.8 CDX2 KRT20 MUC1
21 pyloric antrum cancer 10.8 CDH1 CDX2 MUC2
22 ductal carcinoma in situ 10.8 CCND1 CDH1 TP53
23 acute dacryoadenitis 10.8 MUC1 MUC2 MUC4
24 oral antidiabetic drugs toxicity or dose selection 10.7 CCND1 PTGS2 TP53
25 breast mucinous cystadenocarcinoma 10.7 CDX2 KRT20 MUC2
26 sohval soffer syndrome 10.7 CDX2 MUC1 MUC2
27 fibroma 10.7 CDX2 KRT20 MUC1
28 vulvar keratoacanthoma-like carcinoma 10.7 MUC1 MYC TP53
29 integumentary system cancer 10.7 CCND1 CDH1 TP53
30 childhood teratoma of the ovary 10.7 CDH1 CDX2 KRT20
31 mesenchymoma 10.7 CDX2 KRT20 MUC1
32 frontal sinus schneiderian papilloma 10.7 CDX2 PTGS2 TP53
33 pseudohermaphroditism, male, with gynecomastia 10.7 MUC1 MUC2 MUC4
34 neuroendocrine tumor 10.7 CDX2 KRT20 PTGS2
35 sebaceous adenocarcinoma 10.7 MUC1 MUC4 TP53
36 hodgkin's lymphoma, mixed cellularity 10.7 CCND1 CDH1 TP53
37 fasciolopsiasis 10.7 KRT20 PTGS2 TP53
38 unilateral retinoblastoma 10.7 CCND1 MYC TP53
39 urinary system disease 10.7 MUC1 MUC2
40 extrinsic cardiomyopathy 10.7 KRT20 MUC1 TP53
41 pharynx cancer 10.7 CCND1 MYC TP53
42 chikungunya 10.7 MUC1 MYC TP53
43 fallopian tube leiomyosarcoma 10.7 CDH1 MUC1 MUC2 TP53
44 desmoid disease, hereditary 10.7 CCND1 CDH1 MYC
45 striated muscle rhabdoid tumor 10.6 KRT20 MUC1 MUC2 TP53
46 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 10.6 CDX2 PTGS2 TP53
47 choriocarcinoma 10.6 KRT20 MUC1 MUC2 TP53
48 post-surgical hypoinsulinemia 10.6 CCND1 MYC TP53
49 ureter adenocarcinoma 10.6 CDH1 CDX2 MUC1 MUC2
50 spastic ataxia 3 10.6 CDX2 KRT20 MUC1 TP53

Graphical network of the top 20 diseases related to Bile Duct Carcinoma:



Diseases related to Bile Duct Carcinoma

Symptoms & Phenotypes for Bile Duct Carcinoma

UMLS symptoms related to Bile Duct Carcinoma:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Bile Duct Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.17 CCND1 CDH1 CDX2 FASLG KRT19 MAPK8
2 cellular MP:0005384 10.14 KRT19 KRT7 MAPK8 MUC2 MYC PTGS2
3 digestive/alimentary MP:0005381 10.07 MAPK8 MUC2 MYC PTGS2 TP53 CCND1
4 endocrine/exocrine gland MP:0005379 10.06 CCND1 CDH1 CDX2 FASLG KRT19 MAPK8
5 integument MP:0010771 9.91 CCND1 CDH1 FASLG KRT19 MAPK8 MYC
6 liver/biliary system MP:0005370 9.7 ABCC2 ABCC3 FASLG MAPK8 MYC PTGS2
7 neoplasm MP:0002006 9.65 CCND1 CDH1 CDX2 FASLG KRT19 MAPK8
8 reproductive system MP:0005389 9.28 CCND1 CDH1 CDX2 FASLG KRT19 MAPK8

Drugs & Therapeutics for Bile Duct Carcinoma

Drugs for Bile Duct Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 230)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
3
Coal tar Approved Phase 4 8007-45-2
4
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
5 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
6 Anesthetics Phase 4,Phase 3
7 Fibrin Tissue Adhesive Phase 4
8 Hemostatics Phase 4
9 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
10 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Analgesics Phase 4,Phase 3
12 Anti-Inflammatory Agents Phase 4,Phase 3
13 Antirheumatic Agents Phase 4,Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3
15 Analgesics, Non-Narcotic Phase 4
16 Anti-Inflammatory Agents, Non-Steroidal Phase 4
17 Cyclooxygenase 2 Inhibitors Phase 4
18 Cyclooxygenase Inhibitors Phase 4
19 arginine Nutraceutical Phase 4
20 Omega 3 Fatty Acid Nutraceutical Phase 4
21 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Fluorouracil Approved Phase 2, Phase 3, Phase 1 51-21-8 3385
24
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
25
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 97682-44-5, 100286-90-6 60838
26
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
27
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
28
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
31
Ondansetron Approved Phase 3 99614-02-5 4595
32
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
33
Morphine Approved, Investigational Phase 3 57-27-2 5288826
34
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
35
Citalopram Approved Phase 3 59729-33-8 2771
36
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 1 58-05-9 143 6006
37
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3,Phase 1 59-30-3 6037
38 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
39 Anti-Infective Agents Phase 3,Phase 2,Phase 1
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
42 Antiviral Agents Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
44 Dermatologic Agents Phase 3,Phase 2,Phase 1
45 Photosensitizing Agents Phase 3,Phase 2,Phase 1
46 Calcium, Dietary Phase 2, Phase 3,Phase 1
47 Alkylating Agents Phase 2, Phase 3,Phase 1
48 Dihematoporphyrin Ether Phase 3,Phase 2
49 Ether Phase 3,Phase 2
50 Adjuvants, Anesthesia Phase 3

Interventional clinical trials:

(show top 50) (show all 199)

id Name Status NCT ID Phase Drugs
1 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
3 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
4 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
5 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
6 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
7 Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC Active, not recruiting NCT02535117 Phase 4
8 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
9 Laparoscopic Surgery VS RFA for Recurrent HCC Not yet recruiting NCT02785380 Phase 4
10 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
11 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
12 Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy Unknown status NCT01931449 Phase 3
13 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
14 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
15 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
16 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
17 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
18 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
21 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
22 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3 S-1 Chemotherapy
23 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3 GEMCIS;mFolfirinox
24 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
25 Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures Recruiting NCT01721174 Phase 2, Phase 3
26 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
27 ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03230318 Phase 3 ARQ 087
28 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
29 Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers Active, not recruiting NCT02349412 Phase 3
30 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Not yet recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
31 Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma Suspended NCT01859169 Phase 2, Phase 3
32 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
33 Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS) Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
34 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
35 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
36 Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction Withdrawn NCT01622803 Phase 3
37 Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
38 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
39 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
40 Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct Unknown status NCT00010088 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
41 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
42 Calcitriol in Advanced Intrahepatic Cholangiocarcinoma Unknown status NCT01039181 Phase 2 Calcitriol
43 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
44 Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
45 Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas Completed NCT00003923 Phase 2 porfimer sodium
46 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
47 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed NCT01954745 Phase 2 Cabozantinib
48 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
49 A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases Completed NCT00542048 Phase 2 EndoTAG®-1
50 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride

Search NIH Clinical Center for Bile Duct Carcinoma

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Carcinoma

Anatomical Context for Bile Duct Carcinoma

MalaCards organs/tissues related to Bile Duct Carcinoma:

39
Liver, Testes, Small Intestine, Lung, Skin, Pancreas, Breast

Publications for Bile Duct Carcinoma

Articles related to Bile Duct Carcinoma:

(show top 50) (show all 305)
id Title Authors Year
1
A long-term recurrence-free survival of a patient with the mixed adeno-neuroendocrine bile duct carcinoma: A case report and review of the literature. ( 28806619 )
2017
2
Survival outcome and prognostic factors after pancreatoduodenectomy for distal bile duct carcinoma: a retrospective multicenter study. ( 28612115 )
2017
3
Mesothelin-targeting chimeric antigen receptor-modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. ( 28381173 )
2017
4
Reduced EBP50 expression levels are correlated with unfavorable clinicopathological features of extrahepatic bile duct carcinoma and promote the proliferation and migration of QBC939 cells. ( 28454463 )
2017
5
Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. ( 26956004 )
2016
6
Bile duct carcinoma associated with congenital biliary dilatation in a 16-year-old female: a case report and literature review. ( 26943681 )
2016
7
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. ( 27020207 )
2016
8
Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. ( 27469329 )
2016
9
Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report. ( 27784337 )
2016
10
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. ( 26001650 )
2015
11
Bilateral ovarian metastasis from distal common bile duct carcinoma developing after choledochal cyst excision. ( 26155281 )
2015
12
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma. ( 26423666 )
2015
13
Abnormal increased re-released Hb from RBCs of an intrahepatic bile duct carcinoma patient was detected by electrophoresis release test. ( 26405982 )
2015
14
Polypoid extrahepatic bile duct carcinoma morphologically indistinguishable from benign giant cell tumor. ( 26256450 )
2015
15
A novel technique for endoscopic transpapillary "mapping biopsy specimens" of superficial intraductal spread of bile duct carcinoma (with videos). ( 24674353 )
2014
16
When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma. ( 24657986 )
2014
17
How to access photodynamic therapy for bile duct carcinoma. ( 25332999 )
2014
18
A case of occupational bile duct carcinoma following exposure to a chlorinated organic solvent in the printing industry that was recognized as a work-related accident. ( 25482911 )
2014
19
Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. ( 24289902 )
2013
20
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma. ( 22835954 )
2013
21
Pancreaticobiliary maljunction is associated with common bile duct carcinoma: a meta-analysis. ( 24489507 )
2013
22
Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma. ( 23269460 )
2013
23
Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma. ( 23382894 )
2013
24
Descriptive epidemiology of bile duct carcinoma in Osaka. ( 24014885 )
2013
25
Differential expression of basement membrane type IV collagen I+2 and I+6 chains as a prognostic factor in patients with extrahepatic bile duct carcinoma. ( 22927259 )
2013
26
Bile duct carcinoma involving the common channel associated with pancreaticobiliary maljunction shows an extension pattern similar to ductal carcinoma of the pancreas. ( 23957917 )
2013
27
Duct of Luschka diagnosed by sonography in a patient with bile duct carcinoma and intrahepatic bile duct dilatation. ( 23055263 )
2012
28
Photodynamic therapy using talaporfin sodium (LaserphyrinAr) for bile duct carcinoma: a preliminary clinical trial. ( 23155262 )
2012
29
Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields. ( 21785970 )
2012
30
Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma. ( 22795356 )
2012
31
Extended right hepatectomy for hilar bile duct carcinoma using the modified liver hanging maneuver. ( 22683977 )
2012
32
Down-regulation of c-Myc expression inhibits the invasion of bile duct carcinoma cells. ( 21557726 )
2011
33
Endoscopic diagnosis of extrahepatic bile duct carcinoma: Advances and current limitations. ( 21611097 )
2011
34
Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma. ( 21360081 )
2011
35
Post-cholecystectomy amputation neuroma mimicking common bile duct carcinoma. ( 21861328 )
2011
36
Aggressive hilar inflammatory myofibroblastic tumor with hilar bile duct carcinoma in situ. ( 22319741 )
2011
37
Extensively spreading intraepithelial bile duct carcinoma causing multiple bile duct strictures: report of three cases. ( 21969205 )
2011
38
The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. ( 19596119 )
2010
39
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma. ( 20185162 )
2010
40
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. ( 19521656 )
2010
41
Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. ( 20459570 )
2010
42
Pancreatoduodenectomy for local intrapancreatic recurrence after bile duct resection of mid bile duct carcinoma. ( 21410028 )
2010
43
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( 20224968 )
2010
44
Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. ( 19054142 )
2009
45
Eosinophilic cholangitis with obstructive jaundice mimicking bile duct carcinoma. ( 19194647 )
2009
46
Characteristics of bile duct carcinoma with superficial extension in the epithelium. ( 19363579 )
2009
47
Three-dimensional cholangiography applying C-arm computed tomography in bile duct carcinoma: a new radiological technique. ( 19621666 )
2009
48
IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. ( 19467694 )
2009
49
Expression of syndecan-1 and E-cadherin is inversely correlated with poor patient's prognosis and recurrent status of extrahepatic bile duct carcinoma. ( 19420730 )
2009
50
Pyogenic liver abscess complicating early bile duct carcinoma in the middle bile duct: a rare presentation. ( 19252355 )
2009

Variations for Bile Duct Carcinoma

Cosmic variations for Bile Duct Carcinoma:

9 (show top 50) (show all 689)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM4172016 TSC1 biliary tract,bile duct,carcinoma,adenocarcinoma c.737+1G>A p.? 15
2 COSM308173 TRIM28 biliary tract,bile duct,carcinoma,adenocarcinoma c.1475G>T p.R492L 15
3 COSM44463 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.848G>T p.R283L 15
4 COSM10656 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.742C>T p.R248W 15
5 COSM44329 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.470T>A p.V157D 15
6 COSM10812 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.722C>T p.S241F 15
7 COSM10705 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.586C>T p.R196* 15
8 COSM43687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.641A>G p.H214R 15
9 COSM10704 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.844C>T p.R282W 15
10 COSM10663 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.916C>T p.R306* 15
11 COSM10660 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.818G>A p.R273H 15
12 COSM10654 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.637C>T p.R213* 15
13 COSM44326 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.706T>C p.Y236H 15
14 COSM45393 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.793C>A p.L265M 15
15 COSM44114 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.826G>A p.A276T 15
16 COSM10725 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.701A>G p.Y234C 15
17 COSM43842 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.770T>C p.L257P 15
18 COSM44823 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.981T>G p.Y327* 15
19 COSM10731 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.707A>G p.Y236C 15
20 COSM43778 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.713G>T p.C238F 15
21 COSM44426 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.568C>G p.P190A 15
22 COSM44785 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.702C>G p.Y234* 15
23 COSM11582 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.395A>G p.K132R 15
24 COSM43751 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.673-1G>A p.? 15
25 COSM44523 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.863A>G p.N288S 15
26 COSM10727 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.438G>A p.W146* 15
27 COSM44786 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.694A>C p.I232L 15
28 COSM43596 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.841G>A p.D281N 15
29 COSM10690 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.473G>A p.R158H 15
30 COSM44262 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.808T>C p.F270L 15
31 COSM11078 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.1027G>T p.E343* 15
32 COSM11356 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.726C>G p.C242W 15
33 COSM10883 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.731G>A p.G244D 15
34 COSM10672 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.577C>T p.H193Y 15
35 COSM11355 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.737T>C p.M246T 15
36 COSM10893 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.824G>A p.C275Y 15
37 COSM45025 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.488A>C p.Y163S 15
38 COSM44623 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.487T>A p.Y163N 15
39 COSM44271 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.688A>C p.T230P 15
40 COSM10742 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.578A>G p.H193R 15
41 COSM43909 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.817C>A p.R273S 15
42 COSM3728361 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.782+2T>G p.? 15
43 COSM10687 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.527G>A p.C176Y 15
44 COSM10777 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.715A>G p.N239D 15
45 COSM45050 TP53 biliary tract,bile duct,carcinoma,adenocarcinoma c.871A>G p.K291E 15
46 COSM308164 SYNJ2 biliary tract,bile duct,carcinoma,adenocarcinoma c.811C>A p.L271M 15
47 COSM308304 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.1659A>G p.*553W 15
48 COSM84440 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.346C>T p.Q116* 15
49 COSM14169 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.988G>A p.E330K 15
50 COSM308305 SMAD4 biliary tract,bile duct,carcinoma,adenocarcinoma c.404G>A p.R135Q 15

Expression for Bile Duct Carcinoma

Search GEO for disease gene expression data for Bile Duct Carcinoma.

Pathways for Bile Duct Carcinoma

Pathways related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 32)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.74 CDH1 FASLG MAPK8 PTGS2 TP53
2 12.43 CDH1 KRT19 KRT20 KRT7 MUC1
3
Show member pathways
12.39 CDH1 MAPK8 MUC1 MYC TP53
4 12.36 CCND1 MAPK8 MYC TP53
5
Show member pathways
12.33 CCND1 FASLG MYC TP53
6 12.3 CCND1 CDH1 FASLG MAPK8 MYC PTGS2
7 12.29 CCND1 CDH1 MYC TP53
8
Show member pathways
12.23 CCND1 MAPK8 MYC TP53
9 12.21 CCND1 FASLG MYC TP53
10 12.2 CCND1 CDH1 MAPK8 MYC PTGS2 TP53
11
Show member pathways
12.17 CCND1 FASLG MAPK8 TP53
12 12.06 CCND1 CDH1 MYC TP53
13 12.02 CCND1 CDH1 MYC PTGS2 TP53
14 11.96 CCND1 MAPK8 MYC TP53
15 11.89 CCND1 MYC PTGS2 TP53
16 11.77 CCND1 MYC TP53
17 11.72 CCND1 FASLG MAPK8 MYC TP53
18 11.71 CCND1 CDH1 MYC
19 11.7 CCND1 MYC PTGS2
20 11.68 CCND1 MYC PTGS2 TP53
21 11.66 ABCC2 FASLG TP53
22 11.6 CCND1 CDH1 MYC TP53
23 11.49 CCND1 MAPK8 MYC
24 11.49 CCND1 FASLG MUC1 MYC PTGS2 TP53
25 11.46 CCND1 MYC TP53
26 11.39 CCND1 MYC TP53
27 11.38 FASLG MAPK8 TP53
28 11.38 CCND1 FASLG MAPK8 TP53
29 11.24 KRT19 PTGS2 TP53
30 11.03 ABCC2 ABCC3 MAPK8
31 10.81 CCND1 FASLG MAPK8 MYC PTGS2 TP53
32 10.62 ABCC2 ABCC3

GO Terms for Bile Duct Carcinoma

Cellular components related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 8.92 KRT19 KRT20 KRT7 KRT9

Biological processes related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.76 KRT19 KRT20 KRT7 KRT9
2 response to drug GO:0042493 9.65 ABCC2 CCND1 CDH1 MYC PTGS2
3 response to estrogen GO:0043627 9.61 ABCC2 CCND1 KRT19
4 O-glycan processing GO:0016266 9.58 MUC1 MUC2 MUC4
5 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.51 ABCC2 ABCC3
6 cellular response to UV GO:0034644 9.5 MYC PTGS2 TP53
7 maintenance of gastrointestinal epithelium GO:0030277 9.49 MUC2 MUC4
8 mitotic G1 DNA damage checkpoint GO:0031571 9.48 CCND1 TP53
9 cellular chloride ion homeostasis GO:0030644 9.37 ABCC2 FASLG
10 cornification GO:0070268 9.26 KRT19 KRT20 KRT7 KRT9
11 response to organic substance GO:0010033 8.92 CCND1 CDH1 PTGS2 S100P
12 canalicular bile acid transport GO:0015722 8.85 ABCC2

Molecular functions related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATPase-coupled anion transmembrane transporter activity GO:0043225 8.62 ABCC2 ABCC3

Sources for Bile Duct Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....